World Journal of Gastroenterology
Cure8 research brief
Why This Matters
Better biomarkers could help predict relapse and guide treatment changes, reducing reliance on invasive endoscopy and improving disease control for people with IBD.
Who Should Pay Attention
Clinicians, researchers in IBD diagnostics, adult patients with IBD, and newly diagnosed patients interested in monitoring strategies.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This editorial highlights a continuing need for better biomarkers to predict disease activity and relapse in inflammatory bowel disease (IBD). It notes that fecal calprotectin is a useful marker but argues more accurate and prognostic biomarkers are still needed.
The piece comments on a recent Chen et al article and reviews advances in IBD diagnosis and management. The article appears to be an expert commentary/editorial rather than a new primary study; it summarizes current challenges in monitoring IBD and discusses biomarker development and diagnostic approaches.
It emphasizes discrepancies between clinical symptoms, endoscopic findings, and histopathology, and the reliance on endoscopic surveillance. Practical takeaway: this is a high-level review reinforcing why researchers and clinicians continue to search for better tests to predict relapse and guide therapy.
It does not report new biomarker trial results or specific validated alternatives to fecal calprotectin.
Keep In Mind
This is an editorial/commentary reviewing recent advances and gaps; it does not present new trial results or validated replacement tests for fecal calprotectin.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationWorld Journal of Gastroenterology
PublisherBaishideng Publishing Group Inc.
AuthorsM Jesús Fernández-Aceñero
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedSep 14, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The Role of Fecal Calprotectin in The Diagnosis and Severity of Ulcerative Colitis
Fecal calprotectin is a noninvasive stool biomarker used to detect intestinal inflammation and to help distinguish IBD from noninflammatory conditions.
Crohn᾿s Disease and Ulcerative Colitis: The Role of Endoscopic, Hemogram-derived, Nutritional, and Hepatic Scores
Non-invasive biomarkers that reflect mucosal inflammation and systemic disease activity could help reduce reliance on frequent endoscopy and guide monitoring for people with Crohn’s disease or ulcerative colitis.
Oncostatin M as a Complementary Non-Invasive Marker of Endoscopic and Histological Disease Activity in Ulcerative Colitis
A blood biomarker (OSM) that tracks microscopic inflammation could help detect residual disease activity that fecal calprotectin and routine clinical scores miss. That matters because histological inflammation predicts...